Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report

Leukemia volume 27, pages 1174–1177 (2013)Cite this article

Subjects

Although previously tested in an upfront window by the Berlin–Frankfurt–Munster group, the safety and efficacy of rituximab in combination with multiagent chemotherapy regimens in children and adolescents with advanced mature B-cell non-Hodgkin lymphoma (B-NHL) is unknown.1

The trial, COG ANHL01P1, was open to all Children’s Oncology Group (COG) centers in the United States, Canada, Australia and New Zealand. The protocol was approved at each institutional review board. Parents or patients signed informed consent in accordance with the Declaration of Helsinki. The COG-independent Data and Safety Monitoring Committee reviewed safety reports and interim analyses.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010; 28: 3115–3121.

    Article  CAS  PubMed  Google Scholar 

  2. Murphy SB . Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7: 332–339.

    CAS  PubMed  Google Scholar 

  3. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773–2780.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109: 2736–2743.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L et al. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol 2011; 153: 758–763.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 52: 177–181.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zwick C, Murawski N, Pfreundschuh M . Rituximab in high-grade lymphoma. Semin Hematol 2010; 47: 148–155.

    Article  CAS  PubMed  Google Scholar 

  8. Greenwood M . A Report on the Natural Duration of Cancer. Her Majesty's Stationary Office: London, UK, 1929.

    Google Scholar 

  9. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.

    Article  CAS  PubMed  Google Scholar 

  10. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834–4840.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. He YF, Li YH, Wang FH, Jiang WQ, Xu RH, Sun XF et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008; 87: 481–485.

    Article  CAS  PubMed  Google Scholar 

  12. Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol 2012; 30: 387–393.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040–2045.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Linda Rahl, Virginia Davenport and Saumya Pachauri for their assistance in the development and conduct of this trial, and Ms Amber Quinlan and Erin Morris, RN, for their editorial assistance in the development of this manuscript. We would also like to thank Dr James Lynch for his assistance with analyzing the data. This research was funded by the Division of Cancer Treatment, National Cancer Institute, and National Institutes of Health, Department of Health and Human Services (COG) (CA98543-09 and CA98413-09), Pediatric Cancer Research Foundation and the Doris Duke Charitable Foundation. NCI provided support for data collection and analysis, but had no role in data interpretation, writing of the manuscript or the decision on journal submission.

This work was presented in part at the American Society of Clinical Oncology, Chicago, IL, May 2010, and the American Society of Hematology, San Diego, CA, December 2011.

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology/Oncology, Medical City Children’s Hospital, Dallas, TX, USA

    S Goldman

  2. Department of Biostatistics, University of Nebraska, College of Public Health, Omaha, NE, USA

    L Smith & J R Anderson

  3. Department of Pathology, University of Utah, Salt Lake City, UT, USA

    S Perkins

  4. Department of Pediatrics, New York Medical College, Valhalla, NY, USA

    L Harrison & M S Cairo

  5. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    M B Geyer

  6. Department of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, Ohio State University, Columbus, OH, USA

    T G Gross

  7. Department of Pediatric Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    H Weinstein

  8. Department of Pediatric Hematology/Oncology, CHOC Children’s Hospital, Orange, CA, USA

    S Bergeron

  9. Department of Pediatric Hematology/Oncology, University of Hawaii, Honolulu, HI, USA

    B Shiramizu

  10. Department of Cytogenetics, University of Nebraska Medical Center, Omaha, NE, USA

    W Sanger

  11. Department of Pediatrics, Roswell Park Cancer Institute, Roswell Park, Buffalo, NY, USA

    M Barth

  12. Hoffmann-La Roche Inc, Nutley, NJ, USA

    J Zhi

  13. Department of Medicine, New York Medical College, Valhalla, NY, USA

    M S Cairo

  14. Department of Pathology, New York Medical College, Valhalla, NY, USA

    M S Cairo

  15. Department of Microbiology, Immunology and New York Medical College, Valhalla, NY, USA

    M S Cairo

  16. Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA

    M S Cairo

Authors
  1. S Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J R Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Perkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M B Geyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T G Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Weinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Bergeron
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B Shiramizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. W Sanger
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Barth
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Zhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M S Cairo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M S Cairo.

Ethics declarations

Competing interests

TGG is a consultant for Genentech/Roche, Allos Therapeutics, Pfizer Oncology and Eli Lilly. JZ is an employee of Roche. All other authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldman, S., Smith, L., Anderson, J. et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia 27, 1174–1177 (2013). https://doi.org/10.1038/leu.2012.255

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2012.255

This article is cited by

Search

Advanced search

Quick links